FR901228

What FR901228 Means in Everyday Medical Language

FR901228 is another name for the drug romidepsin, which is sold under the brand name Istodax. It is a medicine used to treat certain types of cancer called cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphomas (PTCLs). These are cancers that affect specific white blood cells called T-cells, which are part of the immune system. Romidepsin works by blocking enzymes known as histone deacetylases. These enzymes help cancer cells grow and divide, so blocking them can slow down or stop the cancer cells and may cause them to die.

Why FR901228 Can Matter in Cancer Care

Romidepsin is important because it offers a treatment option for adults with CTCL or PTCL who have already tried other systemic therapies without success. It is given through an intravenous (IV) infusion, usually over four hours, on specific days in a 28-day cycle. This drug has been studied in clinical trials and is approved by the U.S. Food and Drug Administration (FDA) for these uses. Researchers are also exploring its potential in treating other types of cancer, although these uses are still being studied and are not yet approved.

What Patients Might See or Hear About FR901228

Patients may come across the names FR901228, romidepsin, or Istodax in their medical records, treatment plans, or discussions with their healthcare team. Because these names all refer to the same drug, it can sometimes be confusing. It’s helpful to ask your care team to explain what the drug is, how it works, and how it fits into your treatment plan. You may also hear about the drug’s schedule, side effects, and how it is given. Understanding these details can help you feel more informed and involved in your care.

Where the Term FR901228 Might Appear

The term FR901228 can appear in various places, such as medical reports, treatment plans, clinical trial information, or drug information sheets. It may be listed under different names, so comparing the wording can help avoid confusion. If you see this term in your records or hear it during a visit, it’s a good idea to ask your healthcare provider what it means for your specific situation.

What FR901228 Does Not Automatically Mean

Seeing the term FR901228 or romidepsin does not by itself mean a diagnosis or a treatment decision has been made. It is simply the name of a drug that may be part of a treatment plan. The presence of this term in a report or discussion should be understood in context, and it does not guarantee that the drug will be used or that it is the best choice for every patient. Treatment decisions depend on many factors, including the type and stage of cancer, previous treatments, and overall health.

Common Questions to Ask Your Care Team

If you encounter the term FR901228 or romidepsin, consider asking your healthcare team questions such as: What is this drug and how does it work? Is it part of my treatment plan? What are the possible side effects? How is it given and how often? Are there clinical trials involving this drug that I might consider? Understanding these points can help you feel more confident and involved in your care.

How to Read FR901228 in Context

Because FR901228 can appear under different names, it’s important to read it in the context of your medical records or discussions. Don’t assume it means the same thing in every situation. Always ask your care team to explain how this drug relates to your diagnosis, treatment options, or clinical trials. This helps avoid misunderstandings and ensures you get information tailored to your needs.

Safety and Next Steps

This information about FR901228 (romidepsin, Istodax) is educational and not a substitute for medical advice. It cannot decide what is safe or appropriate for any individual. If you see this term in your medical records or hear it from your care team, the best next step is to ask them directly what it means for you. They can explain how this drug fits into your care and answer any questions you have.